This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
XELJANZ is a Janus kinase (JAK) inhibitor that helps regulate an overactive immune system. It helps disrupt JAK pathways from inside the cells, which are believed to play a role in inflammation.
It is an oral, small molecule drug used to treat adults with moderate to severe active rheumatoid arthritis (RA), active psoriatic arthritis, moderate to severe ulcerative colitis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis for children aged 2 and older.
Jump to...
XELJANZ in Gastroenterology or XELJANZ in Rheumatology
Find out more about XELJANZ (tofacitinib citrate) mode of action.
Find the information you need to support your RA patient.
Find the information you need to support your UC patient.
UC Dosing
Find the information you need to support your PsA patient.
Find the information you need to support your pJIA or jPsA patient.
Find the information you need to support your AS patient.
OCTAVE Sustain was a study of patients who had achieved clinical response in the two OCTAVE Induction studies to assess the efficacy and safety of XELJANZ in maintaining remission2
Example
Example
Professor Charlie Lees discusses the prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies.
Example
Example
A three part series looking at addressing behaviours for patients with inflammatory bowel disease.
Anna Karoliina Ylänne discusses why might patients with inflammatory bowel disease be settling for suboptimal therapy.
Completed head-to-head non-inferiority study comparing XELJANZ and adalimumab in patients with inadequate response to MTX3
Example
Example
In this video, Dr James Galloway, respected rheumatologist and researcher, talks about the ORAL Surveillance study and its implications for the use of tofacitinib in the treatment of RA.
Example
Example
Dr Sarah Mackie and Dr Ai Lyn Tan present recent insights into fatigue in RA and PsA. They discuss the discordance between physicians and patients when it comes to assessing fatigue, the association of fatigue with other co-morbidities and clinical outcomes and novel approaches to managing fatigue.
Find a range of articles and training support on our inflammation therapy area on PfizerPro.
Set up a PfizerPro account to access further materials and resources, and receive communication about medicines and vaccines promoted by Pfizer.
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
References:
1. Data on file, Pfizer UK (REF-XEL25316)
2. Sandborn WJ et al. N Engl J Med 2017; 376(18): 1723–1736.
3. Fleischmann R et al. Lancet 2017; 390:457–468
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021